Barinthus Biotherapeutics Acquired | Healthcare M&A Deal

Barinthus Biotherapeutics acquisition: Barinthus Biotherapeutics plc has completed the acquisition of Barinthus Biotherapeutics, a healthcare services other business in England and Wales, for $27,000,000. The target is a clinical-stage biotherapeutics company developing candidates aimed at metabolic and autoimmune diseases, supporting a broader healthcare services other portfolio. The strategic acquisition structure involves a merger acquisition where Barinthus Bio’s wholly owned Delaware subsidiaries acquire Barinthus and Clywedog, positioning the combined company around a novel pipeline. The healthcare M&A is a strategic acquisition with an announced merger acquisition size around $20.25 million to $27 million, with implementation expected via a UK scheme of arrangement subject to High Court of Justice of England and Wales approval.